Tom Winnifrith does not understand Skinbiotherapeutics like I do, his target is all wrong
By Tom Winnifrith | Monday 23 October 2023
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Oh dear, the last time that Elrico/Lemming Investor commented on my analysis was when I said sell Optibiotix (OPTI) at 132p. He said that I did not understand the company properly, yadda, yadda, yadda. The rest is history. Now it seems that I don’t understand Skinbiotherapeutics (SBTX) - where my target is 150p - unlike the great expert who opines on a BB:
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.